[1. E. Tanai and S. Frantz, Pathophysiology of heart failure, Compr. Physiol. 6 (2015) 187–214; https://doi.org/10.1002/cphy.c14005510.1002/cphy.c14005526756631]Search in Google Scholar
[2. P. Anversa, P. Li, A. Malhotra, X. Zhang, M. V. Herman and J. M. Capasso, Effects of hypertension and coronary constriction on cardiac function, morphology, and contractile proteins in rats, Am. J. Physiol. 265 (1993) H713-H724; https://doi.org/10.1152/ajpheart.1993.265.2.H71310.1152/ajpheart.1993.265.2.H7138368372]Search in Google Scholar
[3. B. Vulesevic, M. G. Sirois, B. G. Allen, S. D. Denus and M. White, Subclinical inflammation in heart failure: A neutrophil perspective author links open overlay panel, Can. J. Cardiol. 34 (2018) 717–725; https://doi.org/10.1016/j.cjca.2018.01.01810.1016/j.cjca.2018.01.01829801737]Search in Google Scholar
[4. F. Piccirillo, M. Carpenito, G. Verolino, C. Chello, A. Nusca, M. Lusini, C. Spadaccio, F. Nappi, G. D. Sciascio and A. Nenna, Changes of the coronary arteries and cardiac microvasculature with aging: Implications for translational research and clinical practice, Mech. Ageing Dev. 184 (2019) 111161; https://doi.org/10.1016/j.mad.2019.11116110.1016/j.mad.2019.11116131647940]Search in Google Scholar
[5. P. Balakumar, A. P. Singh and M. Singh, Rodent models of heart failure, J. Pharmacol. Toxicol. Meth. 56 (2007) 1–10; https://doi.org/10.1016/j.vascn.2007.01.00310.1016/j.vascn.2007.01.00317391988]Search in Google Scholar
[6. Y. Matsuzawa and A. Lerman, Endothelial dysfunction and coronary artery disease: Assessment, prognosis and treatment, Coron. Art. Dis. 25 (2014) 713–724; https://doi.org/10.1097%2FMCA.000000000000017810.1097/MCA.0000000000000178422030125365643]Search in Google Scholar
[7. M. M. Alem, Endothelial dysfunction in chronic heart failure: assessment, findings, significance, and potential therapeutic targets, Int. J. Mol. Sci.20 (2019) Article ID 3198; https://doi.org/10.3390/ijms2013319810.3390/ijms20133198665153531261886]Search in Google Scholar
[8. M. Endoh, Amrinone, Forerunner of novel cardiotonic agents, caused paradigm shift of heart failure pharmacotherapy, Circul. Res. 113 (2013) 358–361; https://doi.org/10.1161/CIRCRESAHA.113.30168910.1161/CIRCRESAHA.113.30168923908328]Search in Google Scholar
[9. S. Steven, K. Frenis, M. Oelze, S. Kalinovic, M. Kuntic, M. T. B. Jimenez, K. Vujacic-Mirski, J. Helm-städter, S. Kröller-Schön, T. Münzel and A. Daiber, Vascular inflammation and oxidative stress: Major triggers for cardiovascular disease, Oxid. Med. Cell. Longev. 2019 (2019) Article ID 7092151 (26 pages); https://doi.org/10.1155/2019/709215110.1155/2019/7092151661239931341533]Search in Google Scholar
[10. J. Habibi, A. R. Aroor, N. A. Das, C. M. Manrique-Acevedo, M. S. Johnson, M. R. Hayden, R. Nistala, C. Wiedmeyer, B. Chandrasekar and V. G. DeMarco, The combination of a neprilysin inhibitor (sacubitril) and angiotensin-II receptor blocker (valsartan) attenuates glomerular and tubular injury in the Zucker Obese rat, Cardiovasc. Diabetol. 18 (2019) Article ID 40; https://doi.org/10.1186/s12933-019-0847-810.1186/s12933-019-0847-8643276030909895]Search in Google Scholar
[11. S. Yandrapalli, M. H. Khan, Y. Rochlani and W. S. Aronow, Sacubitril/valsartan in cardiovascular disease: evidence to date and place in therapy, Ther. Adv. Cardiovasc Dis. 12 (2018) 217–231; 10.1177/175394471878453610.1177/1753944718784536]Search in Google Scholar
[12. P. V. M. Romão, R. A. C. Palozi, L. P. Guarnier, A. O. Silva, B. R. Lorençone, S. R. Nocchi, C. C. de Freitas Sari Moura, E. L. B. Lourenço, D. B. Silva and A. Gasparotto Junior, Cardioprotective effects of Plinia cauliflora (Mart.) Kausel in a rabbit model of doxorubicin-induced heart failure, J. Ethnopharmacol.242 (2019) Article ID 112042; https://doi.org/10.1016/j.jep.2019.11204210.1016/j.jep.2019.112042]Search in Google Scholar
[13. R. K. Trivedi, D. J. Polhemus, Z. Li, D. Yoo, H. Koiwaya, A. Scarborough, T. T. Goodchild and D. J. Lefer, Combined angiotensin receptor–neprilysin inhibitors improve cardiac and vascular function via increased no bioavailability in heart failure, J. Am. Heart Assoc. 7 (2018) e008268; https://doi.org/10.1161/JAHA.117.00826810.1161/JAHA.117.008268]Search in Google Scholar
[14. C. W. Yancy, M. Jessup, B. Bozkurt, J. Butler, D. E. Casey, M. M. Colvin, M. H. Drazner, G. S. Filippatos, G. C. Fonarow, M. M. Givertz, S. M. Hollenberg, J. Lindenfeld, F. A. Masoudi, P. E. McBride, P. N. Peterson, L. W. Stevenson and C. Westlake, 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America, Circulation136 (2017) e137–e161; https://doi.org/10.1161/CIR.000000000000050910.1161/CIR.0000000000000509]Search in Google Scholar
[15. Y. Suematsu, S. Miura, M. Goto, Y. Matsuo, T. Arimura, T. Kuwano, S. Imaizumi, A. Iwata, E. Yahiro and K. Saku, LCZ696, an angiotensin receptor-neprilysin inhibitor, improves cardiac function with the attenuation of fibrosis in heart failure with reduced ejection fraction in streptozotocin-induced diabetic mice, Eur. J. Heart Fail. 18 (2016) 386–393; https://doi.org/10.1002/ejhf.47410.1002/ejhf.474]Search in Google Scholar
[16. Q.-Y. Zhao, C.-X. Huang, H. Jiang, E. Okello, X. Wang, Y.-H. Tang and G.-S. Li, Acetylcholine-regulated K+ current remodelling in the atrium after myocardial infarction and valsartan administration, Can. J. Cardiol.25 (2009) e115-8; https://doi.org/10.1016/s0828-282x(09)70069-810.1016/S0828-282X(09)70069-8]Search in Google Scholar
[17. J. V. J. McMurray, M. Packer, A. S. Desai, J. Gong, M. P. Lefkowitz, A. R. Rizkala, J. L. Rouleau, V. C. Shi, S. D. Solomon, K. Swedberg and M. R. Zile, Angiotensin-neprilysin inhibition versus enal-april in heart failure, N. Engl. J Med. 371 (2014) 993–1004; https://doi.org/10.1056/NEJMoa140907710.1056/NEJMoa140907725176015]Search in Google Scholar
[18. A. Strigli, C. Raab, S. Hessler, T. Huth, A. J. T. Schuldt, C. Alzheimer, T Friedrich, P. W. Burridge, M. Luedde and M. Schwake, Doxorubicin induces caspase-mediated proteolysis of KV7.1, Commun. Biol. 1 (2018) Article ID 155; https://doi.org/10.1038/s42003-018-0162-z10.1038/s42003-018-0162-z616225830302399]Search in Google Scholar
[19. G. Tse, Mechanisms of cardiac arrhythmias, J. Arrhythm. 32 (2016) 75–81; https://doi.org/10.1016/j.joa.2015.11.00310.1016/j.joa.2015.11.003482358127092186]Search in Google Scholar
[20. J. Zheng, L. H. C. Michelle, M. M. B. Sattar, Y. Huang and J. S. Bian, Cardioprotective effects of epigallocatechin-3-gallate against doxorubicin-induced cadiomyocyte injury, Eur. J. Pharmacol. 652 (2011) 82–88; https://doi.org/10.1016/j.ejphar.2010.10.08210.1016/j.ejphar.2010.10.08221114975]Search in Google Scholar
[21. E. K. C. Kong, Y. Huang, J. E. Sanderson, K. B. Chen, S. Yu and C. M. Yu, A novel anti-fibrotic agent, baicalein for the treatment of myocardial fibrosis in spontaneously hypertensive rats, Eur. J. Pharmacol. 658 (2011) 175–181; https://doi.org/10.1016/j.ejphar.2011.02.03310.1016/j.ejphar.2011.02.03321371455]Search in Google Scholar
[22. M. Imran, M. D. Quamrul Hassan, M. D. S. Akhtar, O. Rahman, M. Akhtar and A. K. Najmi, Sacubitril and valsartan protect from experimental myocardial infarction by ameliorating oxidative damage in Wistar rats, Clin. Exp. Hypert. 41 (2017) 62–69; https://doi.org/10.1080/10641963.2018.144186210.1080/10641963.2018.144186229595329]Search in Google Scholar
[23. E. De Angelis, M. Pecoraro, M. R. Rusciano, M. Ciccarelli and A. Popolo, Cross-talk between neurohormonal pathways and the immune system in heart failure: A review of the literature, Int. J. Mol. Sci.20 (2019) Article ID 1698; https://doi.org/10.3390/ijms2007169810.3390/ijms20071698648026530959745]Search in Google Scholar
[24. P. M Ridker, E. Danielson, N. Rifai and R. J. Glynn, Valsartan, blood pressure reduction, and C-reactive protein – primary report of the Val-MARC trial, Hypertension48 (2006) 73–79; https://doi.org/10.1161/01.HYP.0000226046.58883.3210.1161/01.HYP.0000226046.58883.3216714425]Search in Google Scholar
[25. S. Toyoda, A. Haruyama, S. Inami, T. Arikawa, F. Saito, R. Watanabe, M. Sakuma, S. Abe, T. Nakajima, A. Tanaka, K. Node and T. Inoue, Effects of carvedilol vs bisoprolol on inflammation and oxidative stress in patients with chronic heart failure, J. Cardiol. 75 (2020) 140–147; https://doi.org/10.1016/j.jjcc.2019.07.01110.1016/j.jjcc.2019.07.01131444140]Search in Google Scholar
[26. W. Szczurek and B. S. Jurkiewicz, Oxidative stress and inflammatory markers – the future of heart failure diagnostics?, Kardiochir. Torakochir. Pol.12 (2015) 145–149; https://doi.org/10.5114%2Fkitp.2015.52856]Search in Google Scholar
[27. W. Jing, N. D. Vaziri, A. Nunes, Y. Suematsu, T. Farzaneh, M. Khazaeli and H. Moradi, LCZ696 (sacubitril/valsartan) ameliorates oxidative stress, inflammation, fibrosis and improves renal function beyond angiotensin receptor blockade in CKD, Am. J. Transl. Res. 9 (2017) 5473–5484.]Search in Google Scholar